Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02162732 · ClinicalTrials.gov registry record · NA
Molecular-Guided Therapy for Childhood Cancer
A NA study, sponsored by Giselle Sholler.
- Completed
- Registry status
- NA
- Development phase
- 186
- Enrollment target
NCT02162732: Completed NA study, sponsored by Giselle Sholler.
NCT02162732 is a NA study that has completed, run by Giselle Sholler. The registered enrollment target is 186 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02162732, a NA study, has completed, sponsored by Giselle Sholler.
- COMPLETED
- Registry status
- NA
- Development phase
- 186 participants
- Enrollment target
Study Summary
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup. This technology includes a genomic report based on DNA exomes and RNA sequencing that will be used to discover new ways to understand cancers and potentially predict the best treatments for patients with cancer in the future.
Primary Outcome
The definition of feasibility is: Enrollment onto study, genomic profile, analysis and report generation completed, tumor board held with treatment decision, treatment review completed, start of treatment, and completion of 1 cycle of therapy.
Interventions
- DEVICE Guided Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2014-07-08 |
| Est. Completion | 2024-01-18 |
| Phase | NA |
What the finished NCT02162732 record still lists
NCT02162732 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Guided Therapy is the first listed.
NCT02162732 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02162732 about?
NCT02162732 is a clinical study titled "Molecular-Guided Therapy for Childhood Cancer". The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup. This technology includes a genomic report based on DNA exomes and RNA sequencing that will be used to discover new ways to understand cancers and potentiall...
What is the current status of trial NCT02162732?
This trial is currently completed. It is a NA study. The enrollment target is 186 participants. The study started on 2014-07-08. Estimated completion is 2024-01-18.
What interventions are being tested in trial NCT02162732?
The interventions under investigation include: Guided Therapy (DEVICE).
Who is sponsoring clinical trial NCT02162732?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02162732's enrollment target sits among peer trials
186 579th of 2000 higher than 1,421 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI